Objective:
To evaluate the long-term safety and efficacy of faricimab in patients with diabetic macular edema (DME) over a four-year period.
Key Findings:
- Over 50% of patients receiving faricimab achieved a potential 20-week dosing interval.
- Best-corrected visual acuity (BCVA) and central subfield thickness (CST) improvements were maintained over four years.
- Patients starting with faricimab reached CST of less than 325 µm faster and with fewer injections compared to those starting with aflibercept.
- Patients switched from aflibercept to faricimab showed a reduction in hard exudates, indicating potential disease improvement.
- Faricimab was well tolerated with a safety profile consistent with previous studies.
Interpretation:
The findings suggest that faricimab is effective for long-term management of DME, providing sustained visual and anatomical improvements while maintaining a favorable safety profile.
Limitations:
- The study primarily focused on patients previously treated with aflibercept, which may limit generalizability.
- Long-term effects beyond four years are not assessed.
Conclusion:
Faricimab demonstrates long-term stability and efficacy in treating DME, supporting its use in clinical practice for sustained management.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
